Photo taken from Memorial Sloan Kettering Radiation Oncology/X
Jul 13, 2024, 13:17
Side effect of fluoropyrimidine-based chemoRT for rectal cancer – Memorial Sloan Kettering Radiation Oncology
Memorial Sloan Kettering Radiation Oncology shared on X:
“This nurse-led multidisciplinary collaboration discusses a rare but (likely underreported) side effect of fluoropyrimidine-based chemoRT for rectal cancer, colorectal cancer. This is an important QOL issue often assumed to be a radiation toxicity but driven by capecitabine.”
Read further.
Source: Memorial Sloan Kettering Radiation Oncology/X
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Mar 29, 2025, 12:32
Mar 29, 2025, 12:06
Mar 29, 2025, 12:00
Mar 29, 2025, 11:58
Mar 29, 2025, 11:36
Mar 29, 2025, 11:26
Mar 29, 2025, 11:03